Keller Rohrback L.L.P. Announces Investigation of Weight-Loss Drug Meridia

/ Source: GlobeNewswire

SEATTLE, Sept. 14, 2010 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. ( ) announces that it is currently investigating the side effects associated with the use of Meridia, a prescription weight-loss drug. Meridia, which contains the appetite suppressant sibutramine, is manufactured and marketed by Abbott Laboratories (NYSE:ABT).

According to a recent study published in the New England Journal of Medicine, people with a history of heart disease that take Meridia may be at an increased risk for a heart attack or a stroke. The study also confirmed concerns that had been previously raised about the safety of the use of Meridia by people with other heart problems.  A Food and Drug Administration ("FDA") advisory committee is scheduled to meet and discuss the possibility of increased regulation for Meridia.  The use of Meridia in Europe was suspended when serious concerns were expressed about its safety. 

If you or someone you know may have been injured as a result of taking Meridia, or you would like more information regarding this investigation, please contact attorney Michael Woerner at (800) 776-6044 or via email at

Keller Rohrback, with offices in Seattle, Phoenix, and New York, has extensive experience with pharmaceutical litigation, including cases involving the diet drugs Fen-Phen and Redux, as well as Propulsid and Vioxx medications.  The efforts of the firm's trial lawyers have resulted in consumers recovering tens of millions of dollars.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome

CONTACT: Keller Rohrback L.L.P. Michael W. Woerner, Attorney 800-776-6044